Safety and Tolerability of Eprosartan in Combination with Hydrochlorothiazide

  title={Safety and Tolerability of Eprosartan in Combination with Hydrochlorothiazide},
  author={Michael B{\"o}hm and A Sachse},
  journal={Drug Safety},
AbstractThe ideal antihypertensive drug should be effective in reducing blood pressure, but have a low incidence of adverse effects. Angiotensin II receptor blockers, such as eprosartan, are as effective as ACE inhibitors in reducing blood pressure, but lack the main adverse effect of ACE inhibitors, namely cough. Eprosartan has been shown to be well tolerated with a placebo-like adverse-effect profile. When given as monotherapy it is effective in reducing blood pressure; however, some patients… 
Eprosartan: a review of its use in hypertension.
Eprosartan is a useful treatment option in the management of a broad range of patients with hypertension, and its use with HCTZ provides a rational combination regimen.
Eprosartan for the treatment of hypertension
Eprosartan is safe, effective and well-tolerated in long-term treatment, either as a monotherapy or in combination with other antihypertensive drugs such as hydrochlorothiazide.
Safety and Tolerability of Fixed-Dose Irbesartan/Hydrochlorothiazide for Rapid Control of Severe Hypertension
Despite more rapid and aggressive BP lowering, initial fixed-dose irbesartan/HCTZ demonstrated a comparable AE profile to irbesARTan monotherapy in patients with severe hypertension.
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers
Aliskiren shows no clinically relevant pharmacokinetic interactions and is generally well tolerated when administered in combination with amlodipine, valsartan, HCTZ or ramipril.
Introduction: The pharmacological profile of eprosartan – implications for cerebrovascular and cardiovascular risk reduction
In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors.
The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension
AT1 receptor antagonists should be considered as a possible first-line treatment or as a component of combination therapy in patients with type 2 diabetes mellitus and microalbuminuria or nephropathy and as an alternative or additional treatment to ACE inhibitors in patientsWith heart failure or left ventricular dysfunction.
A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Eprosartan is effective and well-tolerated in the treatment of mid-to-moderate hypertension, and the DBP response reduction to eprosartsartan was better than that to enalapril and the benefits of both agents cannot be explained solely by their antihypertensive effects.
Eprosartan mesylate is an angiotensin II receptor (AT1) antagonist. Eprosartan is an effective, well tolerated and potent pure competitive antagonist of the AT1 receptor and hence there has been
Determination of eprosartan mesylate and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods.
Two new simple and selective assay methods have been presented for the analysis of eprosartan mesylate and hydrochlorothiazide in pharmaceutical formulations with a high percentage of recovery and good accuracy and precision.


Efficacy and Safety of Eprosartan in Severe Hypertension
It is demonstrated that in patients with severe hypertension, eprosartan is well tolerated and may be more effective than enalapril in reducing systolic blood pressure.
Eprosartan Provides Safe and Effective Long-term Maintenance of Blood Pressure Control in Patients with Mild to Moderate Essential Hypertension
  • B. Levine
  • Medicine
    Current medical research and opinion
  • 2001
In patients with mild to moderate essential hypertension, eprosartan provides reliable blood pressure control in a high proportion of patients, with a safety profile similar to that seen with placebo in short-term, placebo-controlled trials.
The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension
Eprosartan in a single daily dose was shown to be an effective antihypertensive agent and has the potential to improve patient compliance because of the good adverse-effect profile and the simplicity of a singledaily dose.
Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics.
Evidence for the efficacy of low-dose diuretic monotherapy.
Management of hypertension: the role of combination therapy.
A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.
The combination of low dosages of bisoprolol and hydrochlorothiazide may be a rational alternative to conventional stepped-care therapy for the initial treatment of patients with mild to moderate hypertension.
Clinical Efficacy of Eprosartan
Eprosartan provides clinically significant reductions in blood pressure in patients with mild to severe hypertension regardless of age, gender, and race.